Publication | Closed Access

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

Hematological MalignancyThrombosisErythropoiesis-stimulating AgentsBone Marrow FailureHematologyLong-term OutcomeMyelopoiesisDeletion RefractoryMedicineCell TransplantationAplastic AnemiaMyeloid Neoplasia